Adamas Pharma (ADMS) Tops Q1 EPS by 15c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P on track for muted open as Middle East tensions weigh; AI stocks boost Nasdaq
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- S&P on track for muted open as Middle East tensions weigh; AI stocks boost Nasdaq
- Fulcrum Therapeutics to merge with Slate Medicines in all-stock deal
Adamas Reports First Quarter 2021 Financial Results
May 10, 2021 4:02 PM EDTFirst quarter 2021 total revenues of $19.3 million, a 33% increase over first quarter 2020
GOCOVRI New paid prescriptions of 590, an 18% increase over first quarter 2020
EMERYVILLE, Calif.--(BUSINESS WIRE)-- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today reported financial results for the first quarter ended March 31, 2021, and recent corporate highlights.
Our commercial execution is effectively raising awareness of GOCOVRI and its expanded label, enabling more patients, caregivers and... More
